Efficacy of lopinavir–ritonavir combination therapy for the treatment of hospitalized COVID-19 patients: a meta-analysis

Jiawen Deng*,‡, Fangwen Zhou‡,†, Wenteng Hou1, Kiyan Heybati‡,†, Saif Ali1, Oswin Changi‡, Zachary Silver‡,†, Thanansayan Dhivagar1,‡, Harikrishnaa Ba Ramaraju1, Chi Yi Wong1, Qi Kang Zuo§,†, Elizabeth Lapshina‡,† & Madeline Mellett6

1Faculty of Health Sciences, McMaster University, 1280 Main St W, Hamilton, ON, L8S 4L8, Canada
2Mayo Clinic Alix School of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
3Faculty of Science, Carleton University, 1125 Colonel By Dr, Ottawa, ON, K1S 5B6, Canada
4Integrated Biomedical Engineering & Health Sciences Program, McMaster University, 1280 Main St W, Hamilton, ON, L8S 4L8, Canada
5Department of Anesthesiology, Rutgers, New Jersey Medical School, 185 S Orange Ave, Newark, NJ 07103, USA
6Faculty of Science, McGill University, 845 Sherbrooke St W, Montreal, QC, H3A 0G4, Canada
*Author for correspondence: Tel.: +1 613 618 9734; dengj35@mcmaster.ca
‡Contributed equally to the completion of this review, and both serve as co-first authors

Aim: To evaluate the efficacy and safety of lopinavir–ritonavir (LPV/r) therapy in treating hospitalized COVID-19 patients. Materials & methods: Data from randomized and observational studies were included in meta-analyses. Primary outcomes were length of stay, time for SARS-CoV-2 test conversion, mortality, incidence of mechanical ventilation, time to body temperature normalization and incidence of adverse events. Results: Twenty-four studies (n = 10,718) were included. LPV/r demonstrated no significant benefit over the control groups in all efficacy outcomes. The use of LPV/r was associated with a significant increase in the odds of adverse events. Conclusion: Given the lack of efficacy and increased incidence of adverse events, the clinical use of LPV/r in hospitalized COVID-19 patients is not recommended.

First draft submitted: 21 March 2021; Accepted for publication: 8 December 2021; Published online: 31 January 2022

Keywords: adverse events • antiviral • covid-19 • lopinavir • mortality • ritonavir • SARS-CoV-2

In December 2019, a series of acute, atypical cases of pneumonia, characterized by its rapid rate of transmission, was identified in Wuhan, China. The source of the illness was quickly attributed to a new strain of coronavirus, named SARS-CoV-2, and the subsequent disease it caused was dubbed COVID-19 [1,2]. Since the WHO designated COVID-19 as a global pandemic in March 2020 [3,4], researchers around the world have worked tirelessly to identify effective treatment strategies and design vaccines to treat millions of infected patients and reduce the rate of SARS-CoV-2 infections.

Despite the early success of vaccines from Pfizer & BioNTech [5], AstraZeneca [6] and Moderna [7], various obstacles have slowed the manufacturing and distribution of SARS-CoV-2 vaccines [8,9]. Due to these challenges and the drastic increase in COVID-19 cases during the first quarter of 2021 [10], finding an effective treatment regimen for COVID-19 has never been more important. As of 1 March 2020, there were over 5000 registered COVID-19-related clinical trials that are either recruiting, ongoing or completed [11]. However, consensus regarding the clinical management of COVID-19 is still contradictory and unclear [12,13], especially surrounding popular and controversial regimens such as hydroxychloroquine [14,15]. Currently, treatment strategies for combating COVID-19 is largely based on evidence-based guidelines involving repurposed antiviral therapies, such as remdesivir [16], and immunosuppressive drugs, such as corticosteroids (i.e., dexamethasone) [17,18].

Lopinavir–ritonavir (LPV/r) is a protease inhibitor combination used for the treatment of human immunodeficiency virus (HIV) and was also repurposed as a potential antiviral therapy for the treatment of COVID-19 [19]. Initial enthusiasm regarding the efficacy of LPV/r was largely due to its ability to prevent cytotoxicity and reduce
viral load in vitro (20), as well as encouraging in vivo evidence suggesting that LPV/r may have been effective against the severe acute respiratory syndrome (SARS) with low incidences of adverse events in 2004 (21–23). Both lopinavir and ritonavir are competitive inhibitors of viral proteases which prevents the post-translational proteolysis of pre-cursor peptides and the subsequent release of functional viral proteins, resulting in the production of immature viral particles (24,25). They are commonly used in combination due to the low oral bioavailability of lopinavir, which requires ritonavir as a booster to achieve therapeutic drug concentration (26,27). It is postulated that LPV/r may bind to the highly conserved substrate-binding pocket region of the 3C-like protease (3CLpro) of coronaviruses, leading to its anti-coronavirus capabilities (28,29). In silico binding studies involving LPV/r showed that LPV/r is capable of binding to the SARS coronavirus (SARS-CoV) proteases, and it is speculated that LPV/r should be able to bind to the 3CLpro protein of SARS-CoV-2 as well due to the highly conserved nature of the 3CLpro substrate binding site between SARS-CoV and SARS-CoV-2 (30,31).

Current evidence regarding the clinical use of LPV/r is conflicting and of low quality. Several open-labeled international randomized controlled trials (RCTs), including the RECOVERY trial (32), the WHO SOLIDARITY trial (33) and an RCT reported by Cao et al. (34), have all reported a lack of benefits associated with LPV/r treatments in regards to mortality, viral clearance and time to clinical improvements. However, non-randomized observational studies (35–39) have often produced more optimistic results, suggesting that LPV/r may reduce time to viral clearance and viral shedding. The use of LPV/r for treating COVID-19 is still recommended in several countries, including China (in combination with interferon) (40), Egypt, Saudi Arabia, Belgium and Ireland (41), suggesting that the potential efficacy of LPV/r is still recognized, or at least, debated, by national health organizations. Conflicting opinions on the treatment of COVID-19 from medical guidelines could result in public mistrust, further exacerbating potential issues such as vaccine hesitancy (42,43).

Previous systematic reviews and meta-analyses regarding the LPV/r usage for treating COVID-19 patients yielded no statistically significant difference between LPV/r and standard of care in multiple patient-important outcomes, such as mortality, disease progression and length of stay (44,45). However, these early reviews often included a small number of trials with low sample sizes, which may not be able to provide the necessary precision to detect significant treatment effects (46). Most evidence-based guidelines were also based upon major RCTs such as the RECOVERY and SOLIDARITY trials, while not accounting for observational evidence. Lastly, many systematic reviews involving COVID-19 failed to account for data from non-English databases, namely Chinese databases, which may contain many unanalyzed trials due to the large number of COVID-19 cases in China during the early stages of the pandemic (47,48). Given the limitations of previous knowledge synthesis studies, we conducted an updated systematic review and meta-analysis to investigate whether the use of LPV/r, with or without adjuvant therapies, is more beneficial compared with standard of care or adjuvant therapies alone in regards to length of stay, time for positive-to-negative conversion of SARS-CoV-2 nucleic acid tests and mortality in hospitalized patients with COVID-19. We also examined the safety of LPV/r therapy in COVID-19 patients, including incidences of adverse events and severe (grade 3/4) adverse events.

**Methods**

We conducted this systematic review and meta-analysis following recommendations from the Cochrane Handbook for Systematic Reviews of Interventions (49) and in accordance to the PRISMA statements (50). See online Supplementary Table 1 for the completed PRISMA checklist. This review was prospectively registered on PROSPERO (CRD42021241183), the international prospective register of systematic reviews (51).

**Study identification**

We searched the following databases from 1 January 2020 to 10 February 2021 using English search strategies consisting of the keywords 'lopinavir', 'ritonavir', 'lopinavir–ritonavir', 'LPV', 'Norvir' and 'Kaletra' in combination with database-specific COVID-19 search strings provided by the Rudolph Matas Library of the Health Sciences of Tulane University (52): Medical Literature Analysis and Retrieval System Online (MEDLINE), Excerpta Medica Database (EMBASE) and PubMed. Additionally, we systematically searched the following Chinese databases from 1 January 2020 to 10 February 2021 using a custom Chinese search strategy: Wanfang Data, Wanfang Med Online, SinoMed, China National Knowledge Infrastructure (CNKI) and Chongqing VIP Information (CQVIP). The search strategies used for the database searches can be found in online Supplementary Tables 2–9. We did not impose language restrictions during our study identification and selection processes.
Due to potential biased or problematic COVID-19 studies being published on preprint repositories [53–55], we opted to limit our literature search to peer-reviewed sources only. We also hand-searched the reference sections of two previous systematic reviews [44,45] for relevant studies that were not identified by our database searches.

**Eligibility criteria**

We included both RCTs and comparative non-randomized observational studies that satisfied the following inclusion criteria in our analysis: compared LPV/r with standard of care, or compared LPV/r with adjuvant therapies to adjuvant therapies alone, included laboratory-confirmed, hospitalized COVID-19 patients. While we included studies involving LPV/r with adjuvant therapies, we only included studies that used the same concurrent therapy for its intervention and control arms to minimize the effect of adjuvant therapies on treatment outcomes, similar to the design of several other meta-analyses [56–58].

**Outcome measures**

Our primary outcomes include: length of stay, time for positive-to-negative SARS-CoV-2 nucleic acid tests, mortality at the latest follow-up, incidence of mechanical ventilation, time to normalization of body temperature and incidence of adverse events. Our secondary outcomes include: rate of positive-to-negative conversion at day 7 and day 14, and incidence of severe (grade 3/4) adverse events.

**Study selection**

We performed title and abstract screening using Rayyan (https://rayyan.qcri.org/) [59] independently and in duplicate based on the eligibility criteria. Included abstracts were entered into an independent and in duplicate full text screening process. We resolved disagreements by recruiting a senior author to attain consensus. Figure 1 shows the PRISMA flowchart [60] of our study selection process.

**Data extraction**

We performed data extraction independently and in duplicate using extraction sheets developed *a priori*. We extracted information relating to baseline demographics, descriptions of study methodology, treatment descriptions and outcome measures. The full list of extracted items can be found on our PROSPERO registration.

**Risk of bias assessment**

We assessed the risk of bias in the included RCTs using the revised Cochrane risk of bias tool for randomized trials (RoB2) [61]. The risk of bias in non-randomized observational studies was assessed using the risk of bias in non-randomized studies of interventions (ROBINS-I) [62]. Reviewers judged the risk of bias in each RoB2 or ROBINS-I domain independently and in duplicate, and resolved disagreements by consulting with a senior author.

**Quality of evidence**

We assessed the quality of evidence for our primary outcomes using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) framework [63,64]. The GRADE approach evaluates the quality of evidence by assessing the following domains: study limitations (risk of bias) [65], indirectness [66], inconsistency [67], imprecision [68] and publication bias [69]. Quality of evidence may also be rated up due to magnitude of effects, dose-response gradients and plausible confounders [70]. The overall quality of evidence for each outcome was rated as either high, moderate, low or very low [71], and the results of the primary outcomes and GRADE ratings were presented in a GRADE summary of findings table [72] generated using the GRADEpro online software (https://gradepro.org/) [73].

**Statistical analysis**

We conducted all statistical analyses using R 4.0.4 (https://www.r-project.org/) [74], and we performed random-effects meta-analyses using the *meta* 4.18 library (https://cran.r-project.org/web/packages/meta/) [75]. We expressed and pooled the treatment effects of dichotomous outcomes as odds ratios (ORs) and 95% confidence intervals (CIs), and we also calculated the number needed to treat (NNT) and harm (NNH) [76] for dichotomous outcomes. We reported the treatment effect of continuous outcomes as mean differences (MDs) and 95% CIs.
Records identified on CNKI  
\( n = 366 \)

Records identified on CQVIP  
\( n = 67 \)

Records identified on EMBASE  
\( n = 1374 \)

Records identified on MEDLINE  
\( n = 887 \)

Records identified on PubMed  
\( n = 750 \)

Records identified on SinoMed  
\( n = 224 \)

Records identified on Wanfang data  
\( n = 205 \)

Records identified on Wanfang med online  
\( n = 66 \)

Records after 1909 duplicates removed  
\( n = 2030 \)

Excluded  
\( n = 1006 \)

Wrong study design (animal model, in vitro, etc.)  
\( n = 1115 \)

Wrong publication type (reviews, case studies, etc.)  
\( n = 520 \)

Wrong drug (do not include LPV/r regimens)  
\( n = 193 \)

Wrong condition (not COVID-19)  
\( n = 78 \)

Excluded  
\( n = 100 \)

Ineligible intervention arms  
\( n = 24 \)

Single-arm studies  
\( n = 20 \)

No relevant outcomes  
\( n = 17 \)

Review articles  
\( n = 12 \)

Duplicate  
\( n = 9 \)

Case studies  
\( n = 8 \)

Trial protocols  
\( n = 6 \)

Inaccessible  
\( n = 4 \)

Figure 1. **PRISMA flowchart for the identification and selection of studies.**

CNKI: China National Knowledge Infrastructure; CQVIP: Chongqing VIP Information; EMBASE: Excerpta Medica Database; LPV/r: Lopinavir–ritonavir; MEDLINE: Medical Literature Analysis and Retrieval System Online.

**Missing data & rare events**

For studies with missing data required for analysis, including the mean outcome value and measure of variance for continuous outcomes, attempts were made to contact corresponding authors to obtain unpublished data. For studies that presented continuous outcomes in median and interquartile range (IQR), we assumed that the outcome data is normally distributed and used methods recommended by Luo et al. [77] and Wan et al. [78] to estimate the mean and standard deviation (SD) for analysis. We tested the impact of this assumption by conducting a subgroup analysis comparing the pooled results from studies with estimated mean and SD to studies that did not require estimation.

For studies reporting zero events in one of its treatment arms, we applied a continuity correction factor of 0.5 [79] to complete the meta-analysis. We did not include studies that reported zero events in all treatment arms in our analyses.

**Heterogeneity assessment**

We assessed the presence of heterogeneity using the Cochran’s Q test [80] with a significance level of \( p < 0.10 \), as recommended by the Cochrane Handbook [49]. Heterogeneity was quantified using I^2 statistics [80,81]. We interpreted 30% < I^2 < 75% as moderate heterogeneity and I^2 ≥ 75% as serious heterogeneity [49].
Efficacy of lopinavir–ritonavir combination therapy for the treatment of hospitalized COVID-19 patients

Publication bias
We drew funnel plots [49] to identify small study effects within our included studies as a signal for the presence of publication bias, and we used Egger’s regression test to quantitatively evaluate asymmetry within the funnel plots [82]. Egger’s regression test was not conducted if fewer than 10 studies were included in the analysis, as the test may lack power in these circumstances [83]. We used the trim-and-fill method [84,85] to estimate the number of missing, unpublished studies and to observe the impact of unpublished studies on the pooled treatment effect when potential publication bias is detected.

Meta-regression & subgroup analysis
We performed meta-regression analyses on the proportion of patients with severe disease, defined according to individual study criteria. We performed subgroup analyses based on factors defined a priori: study design (randomized vs nonrandomized), adjuvant regimens and daily LPV/r dosage. For the outcome of mortality, we also conducted a meta-regression to examine the impact of different follow-up durations on the treatment effect. We planned to conduct subgroup analyses based on risk of bias rating (low/some concerns RoB2 vs high RoB2 + serious/critical ROBINS-I). However, this was not completed as only observational studies were included in the high risk subgroup, and only RCTs were included in the low risk subgroup. This observation makes the subgroup analysis by risk of bias rating redundant.

Results
Included studies
We identified and screened 2030 (after deduplication using Endnote 20 [https://endnote.com/]) potentially eligible titles/abstracts. One hundred and twenty four full texts were retrieved and screened. Four RCTs [32–34,86] and 20 observational studies [36–38,87–103] were ultimately included in the systematic review and meta-analysis (Figure 1) with a total of 10,718 hospitalized COVID-19 patients. Characteristics of included studies are tabulated in Table 1.

Risk of bias
The risk of bias in the included RCTs was assessed using RoB2 (Figure 2A). Three RCTs [32–34] were rated as having some concerns for risk of bias due to their unblinded, open-label design. The remaining RCT by Li et al. [86] was rated as having a low risk of bias.

The risk of bias in included observational studies was assessed using ROBINS-I (Figure 2B). Ten studies [36,38,87,89–91,93–95,97,98,100,103] were rated as having a serious risk of bias, while ten studies [37,38,89–92,96,99,101,102] were rated as having a critical risk of bias. Five studies [36,38,89,90,103] were rated as having a serious risk of bias due to confounding factors, while one study [37] was rated as having a critical risk of bias due to either a lack of reporting for important patient characteristics (e.g., disease severity) or an imbalance in the reported patient characteristics. In terms of risk of bias due to selection of participants, three studies [38,92,103] were rated as having a serious risk of bias due to suspected selection bias, such as only including discharged patients in retrospective analyses. Five studies [37,38,90,92,96] were rated as having a serious risk of bias due to classification of interventions, mainly due to poorly defined inclusion criteria (e.g., studies that included patients who had received any LPV/r treatment during hospitalization without describing the LPV/r regimen). Two studies [37,96] were rated as having a serious risk of bias due to deviations from the intended interventions due to imbalances in the adjuvant therapy received between treatment arms. Lastly, two studies [101,102] were rated as having a serious risk of bias due to missing patient outcome data. Risk of bias due to selection of reported results cannot be evaluated for all observational studies because none of the studies provided their respective study protocols.

Treatment efficacy
Mortality
A total of 17 studies [32–34,37,38,86,88–96,101,103] (4 RCTs and 13 observational studies) with 10,105 patients examined the effect of LPV/r on mortality in hospitalized COVID-19 patients. Three studies [37,86,88] reported 0 death in all treatment arms and were excluded from the meta-analysis. The pooled OR was 0.77 (95% CI: 0.45–1.30) with significant and moderate heterogeneity (P_Q = 0.01, I^2 = 64%; Figure 3). The NNT was 26.2 patients.
| Study (year) | Design | Country | Treatment arms | Treatment description | Sample size (n) | Patients with severe disease (n) | F/M | Age (years)† | Treatment duration (days) | Ref. |
|-------------|--------|---------|----------------|-----------------------|----------------|---------------------------------|-----|--------------|---------------------------|------|
| Cao et al. (2020) | Parallel RCT | China | LPV/r | 0.4 g LPV + 0.1 g RTV, b.i.d. | 99 | 99 | 38/61 | 58 (50–68) | 14 | [14] |
| | | | | Standard of Care | | | | | | | |
| | | | | Antibiotics, vasopressor, renal-replacement therapy, supplemental oxygenation and ventilation | 100 | 100 | 41/59 | 58 (48–68) | | |
| Echarte-Morales et al. (2021) | Prospective cohort | Spain | LPV/r + HCQ + AZM | HCQ + AZM, 0.2 g LPV + 0.5 g RTV b.i.d. | 114 | – | 48/66 | 69 (18) | 14 | [93] |
| | | | | HCQ + AZM | 54 | – | 22/32 | 65 (13) | | 5 |
| Gao et al. (2020) | Retrospective cohort | China | LPV/r | LPV/r 500 mg, b.i.d. | 51 | 0 | 21/30 | 33 (27–41) | 7 | [88] |
| | | | | Standard of care | | | | | | | |
| | | | | – | 59 | 0 | 29/30 | 30 (23–45) | | | |
| Grimaldi et al. (2020) | Retrospective cohort | France/Belgium | LPV/r | | 57 | – | 11/46 | 63 (12) | | – |
| | | | | | | | | | | |
| Hraiech et al. (2020) | Retrospective cohort | France | LPV/r | LPV/r 800 mg q.d. | 13 | – | 4/9 | 62 (13) | | – |
| | | | | Standard of care | | | | | | | |
| | | | | – | 85 | – | 21/64 | 63 (11) | | | |
| Chen et al. (2020) | Retrospective cohort | China | LPV/r + IFN-α2b | IFN-α2b, 0.2 g LPV + 0.05 g RTV x2 b.i.d. | 52 | 0 | 25/27 | 47 (35–60) | | 5 |
| | | | | IFN-α2b | 48 | 4 | 24/24 | 55 (36–62) | | 5 |
| Wang et al. (2020) | Retrospective cohort | China | LPV/r | 0.2 g LPV + 0.05 g RTV x2 b.i.d. | 34 | 34 | 9/25 | 66 (53–83) | LOS | [103] |
| | | | | Standard of care | | | | | | | |
| | | | | – | 22 | 22 | 5/17 | 76 (71–86) | LOS | | |
| Karolyi et al. (2020) | Prospective cohort | Austria | LPV/r | 0.4 g LPV + 0.1 g RTV b.i.d. | 47 | – | 15/32 | 65 (49–72) | 7 | [94] |
| | | | | Standard of care | | | | | | | |
| | | | | – | 89 | – | 43/46 | 77 (60–81) | | | |
| Leconnier et al. (2020) | Retrospective cohort | France | LPV/r | LPV/r 400 mg b.i.d. | 20 | 20 | 5/15 | 55 (49–61) | 4 | [91] |
| | | | | Standard of care | | | | | | | |
| | | | | – | 22 | 22 | 4/18 | 63 (54–70) | | | |
| Levy et al. (2020) | Retrospective cohort | France | LPV/r | 0.4 g LPV + 0.1 g RTV b.i.d. | 12 | – | 5/7 | 61 (54–73) | 14 | [89] |
| | | | | Standard of care | | | | | | | |
| | | | | – | 30 | – | 10/20 | 64 (53–69) | | | |
| Li et al. (2020) | Parallel RCT | China | LPV/r | 0.2 g LPV + 0.05 g RTV x2 b.i.d. | 34 | 0 | 17/17 | 50 (15) | 7–14 | [86] |
| | | | | Standard of care | | | | | | | |
| | | | | – | 17 | 0 | 10/7 | 44 (13) | 7–14 | |
| Liu et al. (2020) | Retrospective cohort | China | LPV/r + IFN | IFN, LPV/r 500 mg b.i.d. | 65 | – | 33/32 | 37 (14) | | – |
| | | | | IFN | 37 | – | 16/21 | 37 (33) | | | |

†Age is presented as mean (SD) or median (IQR) unless otherwise specified.

**Legend:**
- ARB: Arbidol/umifenovir
- AZM: Azithromycin
- F: Female
- HCQ: Hydroxychloroquine
- IFN: Interferon
- LPV: Lopinavir
- LPV/r: Lopinavir–ritonavir combination therapy
- M: Male
- RCT: Randomized controlled trial
- RTV: Ritonavir
| Study (year)          | Design        | Country      | Treatment arms | Treatment description                                                                 | Sample size (n) | Patients with severe disease (n) | F/M | Age (years)† | Treatment duration (days) | Ref. |
|----------------------|---------------|--------------|----------------|----------------------------------------------------------------------------------------|----------------|----------------------------------|-----|---------------|----------------------------|------|
| Wang et al. (2020)   | Retrospective cohort | China        | LPV/r + IFN    | –                                                                                        | 83             | 24                              | 28/55 | 53 (42–62) | –                          | [96] |
|                      |               |              | IFN            | –                                                                                        | 39             | 10                              | 23/16 | 52 (41–56) | –                          |      |
| Nathalie et al. (2020) | Retrospective cohort | Switzerland | LPV/r + HCQ    | LPV/r, HCQ                                                                              | 158            | 0                               | 101/57 | 62 (15) | 5                          | [92] |
|                      |               |              | HCQ            | HCQ 0.8 g single dose                                                                   | 93             | 0                               | 38/55 | 66 (16) | –                          |      |
|                      |               |              | LPV/r          | LPV/r 400 mg b.i.d.; For >75 years old, LPV/r 400 mg q.d.a.m. + LPV/r 200 mg q.d.p.m.     | 83             | 0                               | 37/46 | 63 (17) | 5                          |      |
|                      |               |              | Standard of Care | –                                                                                     | 506            | 0                               | 284/222 | 71 (20) | –                          |      |
| Panagopoulos et al. (2020) | Retrospective cohort | Greece | LPV/r + HCQ + AZM | –                                                                                     | 8              | –                               | 2/6   | 56 (19) | –                          | [38] |
|                      |               |              | HCQ + AZM      | –                                                                                        | 8              | –                               | 4/4   | 60 (11) | –                          |      |
| RECOVERY (2020)      | Parallel RCT  | United Kingdom | LPV/r          | 0.4 g LPV + 0.1 g RTV b.i.d.                                                           | 1616           | –                               | 643/973 | 66 (16) | 5                          | [32] |
|                      |               |              | Standard of Care | –                                                                                     | 3424           | –                               | 1320/2104 | 66 (16) | –                          |      |
| Chen et al. (2020)   | Retrospective cohort | China | LPV/r + ARB | ARB, LPV/r 500 mg b.i.d.                                                                 | 35             | 0                               | 23/12 | 43 (11–48) | 7                          | [98] |
|                      |               |              | ARB            | ARB 200 mg b.i.d.                                                                       | 11             | 0                               | 8/3   | 32 (29–65) | 7                          |      |
| Wen et al. (2020)    | Retrospective cohort | China | LPV/r          | 0.2 g LPV + 0.05 g RTV x2 b.i.d.                                                       | 59             | 0                               | 32/27 | 52 (16) | 7                          | [87] |
|                      |               |              | Standard of Care | Nursing, rest, symptom specific and supportive treatment, antibiotics                  | 58             | 3                               | 28/30 | 47 (16) | 7                          |      |
|                      |               |              | LPV/r + ARB    | ARB, LPV/r                                                                              | 25             | 0                               | 17/8  | 49 (17) | 7                          |      |
|                      |               |              | ARB            | ARB 0.1 g x2 t.i.d.                                                                     | 36             | 0                               | 20/16 | 53 (15) | 7                          |      |
| WHO Solidarity Trial (2020) | Parallel RCT  | Multinational | LPV/r          | 0.2 g LPV + 0.05 g RTV x2 b.i.d.                                                       | 1399           | –                               | 548/851 | 14 |                             | [33] |
|                      |               |              | Standard of care | –                                                                                     | 1372           | –                               | 570/802 | 14 |                             |      |
| Xu et al. (2020)     | Retrospective cohort | China | LPV/r          | 0.2 g LPV + 0.05 g RTV x2 b.i.d.                                                       | 64             | 8                               | 40/24 | 51 (17) | 5–10                      | [99] |
|                      |               |              | Standard of care | –                                                                                     | 46             | 2                               | 31/15 | 55 (18) | 5–10                      |      |
| Yan et al. (2020)    | Retrospective cohort | China | LPV/r          | 0.4 g LPV + 0.1 g RTV b.i.d.                                                           | 78             | 25                              | 35/43 | 50 (34–61) | >10                       | [37] |
|                      |               |              | Standard of care | –                                                                                     | 42             | 6                               | 19/23 | 57 (37–66) |                          |      |
| Yao et al. (2020)    | Retrospective cohort | China | LPV/r          | 0.2 g LPV + 0.05 g RTV x2 b.i.d.                                                       | 19             | 6                               | 13/6  | 51 (17) | 7–10                      | [100]|
|                      |               |              | Standard of care | –                                                                                     | 11             | 3                               | 4/7   | 52 (12) | –                          |      |
| Ye et al. (2020)     | Retrospective cohort | China | LPV/r          | 0.4 g LPV + 0.1 g RTV b.i.d. or 0.8 g LPV + 0.2 g RTV q.d.                              | 42             | –                               | 21/21 | –               | –                          | [36] |
|                      |               |              | Standard of care | –                                                                                     | 5              | –                               | 4/1   | –               | –                          |      |
| Yu et al. (2020)     | Retrospective cohort | China | LPV/r          | 0.2 g LPV + 0.05 g RTV x2 b.i.d.                                                       | 108            | 22                              | 56/52 | 48 (16) | 5                          | [101]|
|                      |               |              | Standard of care | –                                                                                     | 114            | 13                              | 61/53 | 51 (17) | 5                          |      |

† Age is presented as mean (SD) or median (IQR) unless otherwise specified.
ARB: Arbidol/umifenovir; AZM: Azithromycin; F: Female; HCQ: Hydroxychloroquine; IFN: Interferon; LPV: Lopinavir; LPV/r: Lopinavir–ritonavir combination therapy; M: Male; RCT: Randomized controlled trial; RTV: Ritonavir.
There were no significant differences between the pooled ORs from any subgroups, although heterogeneity was substantially reduced for the pooled treatment effect from RCTs only ($I^2 = 0\%$; $P_Q = 0.54$; Supplementary Figure 1), studies utilizing a daily regimen of LPV/r 0.8 g ($I^2 = 25\%$; $P_Q = 0.25$; Supplementary Figure 2), and studies utilizing hydroxychloroquine as an adjuvant therapy ($I^2 = 0\%$; $P_Q = 0.43$; Supplementary Figure 3). There were no significant correlations between the proportion of patients with severe disease and the treatment effect based on the meta-regression analysis from six studies [34,91,92,96,101,103] ($p = 0.69$; Supplementary Figure 4). Additionally, there were also no significant correlations between the follow-up duration and the treatment effect based on meta-regression of six studies [32,34,91,93–95] ($p = 0.20$; Supplementary Figure 5).

There was no publication bias based on visual inspection of the funnel plot. This is corroborated by Egger’s regression test, which did not detect any significant small study effect ($P_{Egger} = 0.22$; Supplementary Figure 6).

Length of stay
A total of nine studies [32,34,37,38,92,94,96,100,103] (2 RCTs and 7 observational studies) with 6537 patients examined the effect of LPV/r on length of stay. An observational study conducted by Nathalie et al. [92] was included in the analysis as two separate entries, as the length of stay was reported separately for patients taking hydroxychloroquine adjuvants versus patients who were not taking additional adjuvants beyond standard of care. The pooled MD was 1.56 (95% CI: -0.70–3.82) with significant and severe heterogeneity ($P_Q < 0.01$; $I^2 = 85\%$; Figure 4).
Random effects model

Meta-regression analysis based on six studies [34,37,92,96,100,103] showed no significant correlations between the use of LPV/r and the mortality outcomes in the control groups using standard of care or adjuvant therapies without LPV/r. Heterogeneity was quantified using I² statistics. OR < 1 indicates beneficial treatment effects of LPV/r compared with the control groups.

**Figure 3.** Forest plot for the pooling of odds ratios for mortality. The use of LPV/r was compared with control groups using standard of care or adjuvant therapies without LPV/r. Heterogeneity was quantified using I² statistics. OR < 1 indicates beneficial treatment effects of LPV/r compared with the control groups.

**Table 1.** Study characteristics and outcomes of treatment comparison in patents with COVID-19.

| Study (year) | Experimental | Control | OR | 95% CI | Weight (%) |
|-------------|--------------|---------|----|--------|------------|
| Panagopoulos et al. 2020 | 0 8 3 8 | | 0.09 [0.00; 2.16] | 2.3 |
| Karolyi et al. 2020 | 4 47 32 89 | | 0.17 [0.05; 0.50] | 7.4 |
| Hraiech et al. 2020 | 1 13 5 15 | | 0.17 [0.02; 1.67] | 3.6 |
| J. Wang et al. 2020 | 11 34 11 22 | | 0.48 [0.16; 1.44] | 7.4 |
| Nathalie et al. 2020 | 25 241 106 599 | | 0.54 [0.34; 0.86] | 10.1 |
| Echarte-Morales et al. 2021 | 9 114 7 54 | | 0.58 [0.20; 1.64] | 7.7 |
| Cao et al. 2020 | 19 99 25 100 | | 0.71 [0.36; 1.40] | 9.3 |
| Lecronier et al. 2020 | 7 20 7 22 | | 0.78 [0.22; 2.72] | 6.8 |
| WHO Solidarity Trial 2020 | 148 1399 146 1372 | | 0.99 [0.78; 1.27] | 10.7 |
| RECOVERY 2020 | 374 1616 767 3424 | | 1.04 [0.91; 1.20] | 10.8 |
| Yu et al. 2020 | 5 108 5 114 | | 1.06 [0.30; 3.76] | 6.8 |
| N. Wang et al. 2020 | 1 83 0 39 | | 1.44 [0.06; 36.06] | 2.2 |
| Grimaldi et al. 2020 | 30 57 29 85 | | 2.15 [1.08; 4.26] | 9.2 |
| Levy et al. 2020 | 6 12 4 30 | | 6.50 [1.39; 30.49] | 5.7 |

**Figure 4.** Forest plot for the pooling of mean differences for length of stay. The use of LPV/r was compared with control groups using standard of care or adjuvant therapies without LPV/r. Heterogeneity was quantified using I² statistics. MD < 0 indicates beneficial treatment effects of LPV/r compared with the control groups.

HCQ: Hydroxychloroquine; LPV/r: Lopinavir–ritonavir; OR: Odds ratio.

The use of interferon (IFN) therapy as an adjuvant reported a considerably higher effect (MD: 5.52 [95% CI: 3.26–7.78]) compared with studies using hydroxychloroquine adjuvants (MD: 1.30 [95% CI: -25.48–28.08]) and studies using no adjuvants (MD: 1.09 [95% CI: -2.01–4.20]). There were no significant differences in any of the other subgroup analyses (Supplementary Figures 7–9), although heterogeneity was significantly reduced in the RCT subgroup (P_Q = 0.58; I² = 0%; Supplementary Figure 10).

**Figure 5A.** Funnel plots showing publication bias in the meta-analysis. There was no publication bias based on visual inspection of the funnel plot (Supplementary Figure 12).

Positive-to-negative conversion of SARS-CoV-2 nucleic acid test

A total of nine studies [36–38,86,88,94,97,99,101] (1 RCTs and 8 observational studies) with 914 patients examined the effect of LPV/r on time for positive-to-negative conversion of SARS-CoV-2 nucleic acid tests. The pooled MD was -1.87 (95% CI: -4.00–0.26) with significant and severe heterogeneity (I² = 76%; P_Q < 0.01; Figure 5A).
Meta-Analysis  Deng, Zhou, Hou et al.

There were significant between-group differences for the subgroup analysis by different adjuvant therapies (Supplementary Figure 13), as a study conducted by Panagopoulos et al. [38] that used hydroxychloroquine and azithromycin as adjuvants reported a MD of -4.94 (95% CI: -7.13 to -2.75), which is substantially lower compared with the MD reported by Liu et al. [97] (MD: 1.73 [95% CI: -2.38–5.83]) which used IFN therapy as an adjuvant, as well as the pooled MD of studies that did not use adjuvants beyond standard of care (MD: -1.81 [95% CI: -4.16–0.55]). We did not perform the subgroup analysis by LPV/r regimens, as all studies included in the analysis used the same regimen of LPV/r 1.0 g q.d., with the exception of Panagopoulos et al. [38] which did not report the LPV/r regimens used in the study. There were no significant differences in the MDs between studies of different methodological designs, nor between studies that required imputation versus studies that did not require imputation (Supplementary Figures 14 & 15).

Figure 5. Forest plots for the pooling of mean differences for the outcome of time for positive-to-negative conversion of SARS-CoV-2 nucleic acid test and for the pooling of odds ratios for secondary efficacy outcomes. The use of LPV/r was compared with control groups using standard of care or adjuvant therapies without LPV/r. Heterogeneity was quantified using I² statistics. (A) Forest plot for the pooling of MDs for the outcome of time for positive-to-negative conversion of SARS-CoV-2 nucleic acid test. MD > 0 indicates beneficial treatment effects of LPV/r compared with the control groups. (B) Forest plot for the pooling of ORs for incidences of positive-to-negative nucleic acid test conversions at day 7. (C) Forest plot for the pooling of ORs for incidences of positive-to-negative nucleic acid test conversions at day 14. OR > 1 indicates beneficial treatment effects of LPV/r compared with the control groups for all secondary efficacy outcomes.

LPV/r: Lopinavir–ritonavir; MD: Mean difference; OR: Odds ratio.
Efficacy of lopinavir–ritonavir combination therapy for the treatment of hospitalized COVID-19 patients

Meta-Analysis

Panagopoulos et al. 2020
Cao et al. 2020
Lecronier et al. 2020
WHO Solidarity Trial 2020
J. Wang et al. 2020
Grimaldi et al. 2020
RECOVERY 2020
Levy et al. 2020
Karolyi et al. 2020

Random effects model
Heterogeneity: $I^2 = 32\%$; $p_Q = 0.16$

| Study (year) | Experimental Events | Control Events | OR   | 95% CI | Weight (%) |
|-------------|---------------------|----------------|------|--------|------------|
| Panagopoulos et al. 2020 | 1 8 | 4 8 | 0.14 | [0.01; 1.76] | 5.0 |
| Cao et al. 2020 | 26 99 | 39 100 | 0.56 | [0.31; 1.02] | 15.3 |
| Lecronier et al. 2020 | 5 20 | 6 22 | 0.89 | [0.22; 3.53] | 10.0 |
| WHO Solidarity Trial 2020 | 126 1399 | 121 1372 | 1.02 | [0.79; 1.33] | 17.0 |
| J. Wang et al. 2020 | 21 34 | 13 22 | 1.12 | [0.37; 3.35] | 11.9 |
| Grimaldi et al. 2020 | 20 57 | 27 85 | 1.16 | [0.57; 2.36] | 14.6 |
| RECOVERY 2020 | 152 1556 | 276 3280 | 1.18 | [0.96; 1.45] | 17.2 |
| Levy et al. 2020 | 2 12 | 1 30 | 5.80 | [0.47; 71.07] | 5.1 |
| Karolyi et al. 2020 | 2 47 | 0 89 | 9.84 | [0.46; 209.19] | 3.8 |

Figure 6. Forest plot for the pooling of odds ratios for incidence of mechanical ventilation. The use of LPV/r was compared with control groups using standard of care or adjuvant therapies without LPV/r. Heterogeneity was quantified using $I^2$ statistics. OR $< 1$ indicates beneficial treatment effects of LPV/r compared with the control groups. LPV/r: Lopinavir–ritonavir; OR: Odds ratio.

Meta-regression analysis based on 5 studies [37,86,88,99,101] showed no significant correlations between the proportion of patients with severe disease and the treatment effect ($p = 0.10$; Supplementary Figure 16). There was no publication bias based on visual inspection of the funnel plot (Supplementary Figure 17).

At 7 days after the commencement of LPV/r therapy, the OR of negative SARS-CoV-2 tests in the LPV/r group compared with the control group was 0.85 (95% CI: 0.44–1.65; NNH 25.4 patients) with no significant heterogeneity ($I^2 = 20\%$; $P_Q = 0.28$; Figure 5B) based on six studies [86,87,95,98,102,103]. At 14 days, the OR of negative SARS-CoV-2 tests was 1.03 (95% CI: 0.34–3.16, NNT 144.0 patients) with no significant heterogeneity ($I^2 = 36\%$; $P_Q = 0.19$, Figure 5C) based on four studies [34,86,87,91]. There were no significant differences between the pooled ORs from any subgroups for the aforementioned secondary outcomes (Supplementary Figures 18–22), nor were there any significant correlations between the proportion of patients with severe disease and the treatment effect based on meta-regression analyses (Supplementary Figures 23 & 24). There were no detectable small study effects in any of the aforementioned secondary outcomes based on visual inspections of the funnel plots (Figures 25 & 26).

Incidence of mechanical ventilation

Nine studies [17,33,34,38,89–91,94,103] (3 RCTs and 6 observational studies) with 8240 patients assessed the effect of LPV/r on incidences of mechanical ventilation in hospitalized COVID-19 patients. The pooled OR was 1.04 (95% CI: 0.55–1.97) with no significant heterogeneity ($I^2 = 32\%$; $P_Q = 0.16$; Figure 6). The NNH was 263.3 patients.

There were no significant between-group differences in any of the subgroup analyses (Supplementary Figures 27–29). We did not perform meta-regression analyses due to insufficient data. No evidence of small study effects was observed based on visual inspections of the funnel plot (Supplementary Figure 30).

Time to body temperature normalization

Five studies [36,38,88,99,100] (all retrospective cohort studies) with 313 patients assessed the effect of LPV/r on time to body temperature normalization in hospitalized COVID-19 patients. The pooled MD was -0.04 (95% CI: -2.34–2.25) with significant and substantial heterogeneity ($I^2 = 82\%$; $P_Q < 0.01$; Figure 7).

There were no significant between-group differences in any of the subgroup analyses (Supplementary Figures 31–32). Meta-regression of outcomes from three studies [88,99,100] did not identify a significant correlation between the proportion of patients with severe disease and the treatment effect ($p = 0.20$; Supplementary Figure 33). We did not detect evidence of small study effects based on visual inspections of the funnel plot (Supplementary Figure 34).

Adverse events

A total of six studies [34,86,87,99,101,102] (2 RCTs and 4 observational studies) with 855 patients examined the effect of LPV/r on incidences of adverse events in hospitalized COVID-19 patients. The pooled OR was 2.88 (95% CI: [0.01; 1.76]; [0.31; 1.02]; [0.22; 3.53]; [0.79; 1.33]; [0.37; 3.35]; [0.57; 2.36]).
Figure 7. Forest plot for the pooling of mean differences for time to normalization of body temperature. The use of LPV/r was compared with control groups using standard of care or adjuvant therapies without LPV/r. Heterogeneity was quantified using I² statistics. MD < 0 indicates beneficial treatment effects of LPV/r compared with the control groups. LPV/r: Lopinavir–ritonavir; MD: Mean difference.

Figure 8. Forest plot for the pooling of odds ratios for incidence of adverse events and for pooling of odds ratios for secondary safety outcomes. The use of LPV/r was compared with control groups using standard of care or adjuvant therapies without LPV/r. Heterogeneity was quantified using I² statistics. OR < 1 indicates better safety outcomes of LPV/r compared with the control groups for both forest plots. (A) Forest plot for the pooling of ORs for incidence of adverse events. (B) Forest plot for the pooling of ORs for incidence of severe adverse events. LPV/r: Lopinavir–ritonavir; OR: Odds ratio.

1.04–7.95) with significant but moderate heterogeneity (I² = 67%; p<0.01; Figure 8A). The NNH was 4.6 patients. The most commonly reported adverse events in the LPV/r group were gastrointestinal side effects such as diarrhea, nausea, vomiting, stomach pain and loss of appetite and liver-related toxicities such as elevated liver enzymes and elevated bilirubin.

Subgroup analysis by different LPV/r regimens was not conducted as all studies included in the analysis reported using the same regimen of LPV/r 1.0 g q.d. There were no significant between-group differences in any of the subgroup analyses (Supplementary Figures 35 & 36). Meta-regression analysis of 6 studies showed no significant correlations between the proportion of patients with severe disease and the treatment effect (p = 0.11; Supplementary Figure 37). Visual inspection of the funnel plot showed no significant small study effects (Supplementary Figure 38).
also did not find any benefits associated with LPV with a non-significant increase in length of stay compared with standard of care or adjuvant therapies alone. We CoV-2 nucleic acid tests, or the time to normalization of body temperature. In fact, the use of LPV significantly decrease the odds of death, the length of stay, the time for positive-to-negative conversion of SARS-
pitalized COVID-19 patients. On the basis of very low quality of evidence, we found that LPV
Our systematic review and meta-analysis included 4 RCTs and 20 observational studies involving 10,718 hos-

Main findings

| Primary outcomes | Relative effect (95% CI) | Anticipated absolute effects (95% CI) | Patients, n (studies, n) | Quality of evidence (GRADE) | Comments |
|------------------|--------------------------|-------------------------------------|-------------------------|-----------------------------|----------|
| Mortality        | OR 0.77 (0.45–1.30)      | 189 per 1000                        | Risk without LPV/r       | Risk with LPV/r             | 10,105 (4 RCTs, 13 OSs) | 26 patients need to be treated with LPV/r to prevent one additional death. |
| Length of stay   | –                        | The mean length of stay in the control groups was 14 days | MD 1.56 more days (0.70 fewer to 3.82 more) | MD 1.87 fewer days (4.00 fewer to 0.26 more) | 6,537 (2 RCTs, 7 OSs) | 263 patients need to be treated with LPV/r to cause one additional incidence of mechanical ventilation |
| Time for positive-to-negative conversion of SARS-CoV-2 nucleic acid test | –                        | The mean time in the control groups was 16 days | MD 1.87 fewer days (4.00 fewer to 0.26 more) | 914 (1 RCT, 8 OSs) |
| Incidence of mechanical ventilation | OR 1.04 (0.55–1.97) | 97 per 1000                          | Risk without LPV/r       | Risk with LPV/r             | 8240 (3 RCTs and 6 OSs) | 5 patients need to be treated with LPV/r to cause one additional incidence of adverse events |
| Time to body temperature normalization | –                        | The mean time in the control groups was 8 days | MD 0.04 fewer days (2.34 fewer to 2.25 more) | 313 (5 OSs) |
| Incidence of adverse events | OR 2.88 (1.04–7.95) | 201 per 1000                          | Risk without LPV/r       | Risk with LPV/r             | 855 (2 RCTs and 4 OSs) | 5 patients need to be treated with LPV/r to cause one additional incidence of adverse events |

Two RCTs by Cao et al. [34] and Li et al. [86], which both used a regimen of LPV/r 1.0 g q.d. with no adjuvant therapy beyond standard of care, reported incidences of severe adverse events. The pooled OR was 2.10 (95% CI: 0.85–5.20), with no significant heterogeneity ($I^2 = 0$%; $P_Q = 0.86$; Figure 8B). The NNH was 11.7 patients.

Quality of evidence

The summary of findings for primary outcomes is tabulated in Table 2.

Discussions

Main findings

Our systematic review and meta-analysis included 4 RCTs and 20 observational studies involving 10,718 hospitalized COVID-19 patients. On the basis of very low quality of evidence, we found that LPV/r use did not significantly decrease the odds of death, the length of stay, the time for positive-to-negative conversion of SARS-CoV-2 nucleic acid tests, or the time to normalization of body temperature. In fact, the use of LPV/r was associated with a non-significant increase in length of stay compared with standard of care or adjuvant therapies alone. We also did not find any benefits associated with LPV/r in reducing incidences of mechanical ventilation, based on a low quality of evidence.
The lack of efficacy in LPV/r use as shown by our primary outcomes is supported by results from our secondary outcomes as well, since we did not identify a significant increase in the incidence of positive-to-negative conversions of SARS-CoV-2 nucleic acid tests in the LPV/r group compared with the control group at 7 or 14 days after the start of treatment. In general, results of our subgroup analyses and meta-regressions did not yield any significant findings either, with the exception of two single-study subgroups: Wang et al. [96], which found that the use of an IFN adjuvant therapy with LPV/r significantly increased the length of stay compared with IFN therapy alone, and Panagopoulos et al. [38], which found that the use of hydroxychloroquine + azithromycin in combination with LPV/r resulted in significant reductions in the time for positive-to-negative conversion of SARS-CoV-2 nucleic acid tests compared with only hydroxychloroquine + azithromycin. However, as no data pooling was conducted for these subgroups, it is unknown whether these statistically significant results are due to subgroup factors or confounding variables unique to each study. Notably, Panagopoulos et al. [38] only included 16 patients in their study, which is the lowest sample size among all of our included publications. Previous investigations have found that studies with small sample sizes tend to overestimate treatment effects [104,105]; thus, the significant findings from Panagopoulos et al. [38] may be due to an exaggeration of the treatment effect away from the null and should be interpreted within the context of other similar studies. Nathalie et al. [92] and Echarte-Morales et al. [93] both used hydroxychloroquine as an adjuvant therapy with large sample sizes, and they did not find any significant benefits associated with using LPV/r in combination with hydroxychloroquine (with or without azithromycin) in other primary outcomes, including length of stay and death. This suggests that the results from single-study subgroups with low sample sizes should be interpreted with caution and require further examination in future investigations.

In addition to a lack of efficacy of LPV/r in the treatment of hospitalized COVID-19 patients, our meta-analysis also suggested that LPV/r may result in a significant 180% increase in the odds of adverse events based on moderate heterogeneity and moderate quality of evidence. While we did not specifically analyze the incidences of different categories of adverse events, gastrointestinal side effects and liver-related toxicities were the most commonly reported types of adverse events in the LPV/r group.

Comparison to other studies
The lack of efficacy of LPV/r in COVID-19 patients is consistent with previous systematic reviews, which found that LPV/r did not significantly reduce time to virological cure, time to body temperature normalization, or incidences of cough relief [44]. LPV/r also did not decrease incidences of disease progression or mortality [45].

LPV/r was considered to be a potential treatment regimen for SARS-CoV-2 due to both in vitro and in vivo studies which demonstrated that it may be effective in inhibiting the action of other human coronaviruses, including SARS-CoV and MERS-CoV [21,23,106,107]. However, the most widely cited in vitro study conducted by Chu et al. [21] in SARS-CoV patients, which showed that LPV/r treatments may lower the severity of SARS-CoV symptoms, was an open, non-randomized trial involving a small treatment group and historical controls. The nature of the study design may be subjected to bias, and the results may be exaggerated due to improvements in disease management during the later stages of the 2004 epidemic.

In addition, many in vitro studies yielded different IC50 values in regards to the inhibitory effect of lopinavir on human coronaviruses, from 50 μmol/l in SARS-CoV [107] to 8–12 μmol/l in SARS-CoV-2 [108]. A study conducted by Wu et al. [107] attempted to synthesize lopinavir derivatives in an effort to improve the IC50 of lopinavir against SARS-CoV. However, they were only able to obtain a minimum IC50 of 25 μmol/l [107]. These values are generally greater than the maximum serum concentration (Cmax) of lopinavir, which has been estimated to be 13.5 μmol/l [109], and significantly greater than the unbound Cmax of lopinavir, which has been estimated to be 0.2 μmol/l [110]. The IC50 values of lopinavir against coronaviruses are thousands of folds greater than the IC50 values required to inhibit HIV, which has been estimated to be around 0.004–0.011 μmol/l for lopinavir [108,111].

Given these findings, it has been suggested that the serum concentration of free LPV/r cannot suppress the action of SARS-CoV-2 in vivo, despite optimistic in vitro findings. This conclusion is supported by our current meta-analysis, which found that LPV/r lacks efficacy in a clinical setting.

Apart from the lack of efficacy, previous reviews have also identified an increased incidence of adverse events in the LPV/r group compared with standard of care [44], similar to our findings. Specifically, one review found that the use of LPV/r is significantly associated with a higher incidence of diarrhea [45], which we have also observed in five of our included studies [34,87,99,101,102] although we did not quantitatively analyze the incidence of diarrhea. In addition to gastrointestinal side effects, we also found hepatotoxicity to be widely reported across our included studies. Levy et al. [89] reported observing higher incidences of jaundice and bilirubin elevation in the LPV/r group.

Comparison to other studies
The lack of efficacy of LPV/r in COVID-19 patients is consistent with previous systematic reviews, which found that LPV/r did not significantly reduce time to virological cure, time to body temperature normalization, or incidences of cough relief [44]. LPV/r also did not decrease incidences of disease progression or mortality [45].

LPV/r was considered to be a potential treatment regimen for SARS-CoV-2 due to both in vitro and in vivo studies which demonstrated that it may be effective in inhibiting the action of other human coronaviruses, including SARS-CoV and MERS-CoV [21,23,106,107]. However, the most widely cited in vitro study conducted by Chu et al. [21] in SARS-CoV patients, which showed that LPV/r treatments may lower the severity of SARS-CoV symptoms, was an open, non-randomized trial involving a small treatment group and historical controls. The nature of the study design may be subjected to bias, and the results may be exaggerated due to improvements in disease management during the later stages of the 2004 epidemic.

In addition, many in vitro studies yielded different IC50 values in regards to the inhibitory effect of lopinavir on human coronaviruses, from 50 μmol/l in SARS-CoV [107] to 8–12 μmol/l in SARS-CoV-2 [108]. A study conducted by Wu et al. [107] attempted to synthesize lopinavir derivatives in an effort to improve the IC50 of lopinavir against SARS-CoV. However, they were only able to obtain a minimum IC50 of 25 μmol/l [107]. These values are generally greater than the maximum serum concentration (Cmax) of lopinavir, which has been estimated to be 13.5 μmol/l [109], and significantly greater than the unbound Cmax of lopinavir, which has been estimated to be 0.2 μmol/l [110]. The IC50 values of lopinavir against coronaviruses are thousands of folds greater than the IC50 values required to inhibit HIV, which has been estimated to be around 0.004–0.011 μmol/l for lopinavir [108,111].

Given these findings, it has been suggested that the serum concentration of free LPV/r cannot suppress the action of SARS-CoV-2 in vivo, despite optimistic in vitro findings. This conclusion is supported by our current meta-analysis, which found that LPV/r lacks efficacy in a clinical setting.

Apart from the lack of efficacy, previous reviews have also identified an increased incidence of adverse events in the LPV/r group compared with standard of care [44], similar to our findings. Specifically, one review found that the use of LPV/r is significantly associated with a higher incidence of diarrhea [45], which we have also observed in five of our included studies [34,87,99,101,102] although we did not quantitatively analyze the incidence of diarrhea. In addition to gastrointestinal side effects, we also found hepatotoxicity to be widely reported across our included studies. Levy et al. [89] reported observing higher incidences of jaundice and bilirubin elevation in the LPV/r group.
Efficacy of lopinavir–ritonavir combination therapy for the treatment of hospitalized COVID-19 patients

Meta-Analysis

group compared with standard-of-care, Yu et al. [101] reported elevated transaminase in LPV/r patients, and J. Wang et al. [103] reported elevated aspartate aminotransferase and alanine aminotransferase. Gastrointestinal side effects and hepatotoxicity are both known adverse events associated with the use of LPV/r [112], with some studies reporting a prevalence of liver toxicities as high as 10% in HIV patients using LPV/r [113,114]. Levy et al. [89] noted that hepatotoxicity associated with LPV/r may be particularly problematic for the treatment of COVID-19 patients with obesity, as underlying liver steatosis may be a contributing factor to liver toxicity.

Recent reports have also raised concerns with regards to potential drug–drug interactions associated with LPV/r in the treatment of COVID-19 [115]. When used as a monotherapy, lopinavir has poor oral bioavailability because it is rapidly metabolized by cytochrome P450 enzyme systems [116]. For this reason, ritonavir is often co-formulated with lopinavir to take advantage of ritonavir’s ability to potently inactivate cytochrome P4503A4 (CYP3A4), thus dramatically increasing the serum availability of lopinavir [117,118]. However, inhibition of CYP3A4 may also increase the serum concentration of other drugs that rely on CYP3A4 for metabolism, potentially resulting in drug–drug interactions [119]. For example, systemic corticosteroids (i.e. dexamethasone), which have been recently recommended for use in COVID-19 patients receiving supplemental oxygen [120,121], relies on CYP3A4 for metabolism [122]. Thus, the co-administration of corticosteroids and LPV/r may result in Cushing’s syndrome and adrenal suppression [123,124]. Apart from COVID-19 treatments, medications prescribed for other conditions such as statins [125] and antiarrhythmic drugs [126] may also result in drug–drug interactions with LPV/r [115]. A previous observational study by Macías et al. [115] concluded that drug–drug interactions which contraindicates the use of LPV/r is often overlooked in the context of the ongoing COVID-19 healthcare crisis, signifying that physicians treating COVID-19 patients using LPV/r should be aware of potential interactions associated with CYP3A4 inhibition.

While the guidance from the NIH [127] and IDSA [128] currently recommend against the use of LPV/r, these are primarily based upon major RCTs, namely the RECOVERY and SOLIDARITY trial. The use of LPV/r for the management of COVID-19 patients continues to be recommended in the clinical guidelines across several major countries, including China [40], Egypt, Saudi Arabia, Belgium and Ireland [41]. Our systematic review incorporated both randomized and observational evidence, and considered the impact of dosage on patient-important outcomes to provide comprehensive evidence on LPV/r’s lack of efficacy. Additionally, given the significant number of adverse events associated with LPV/r, our findings could inform the perspectives of clinicians, policy makers and the general public to ensure patient safety.

Strengths & limitations

This systematic review and meta-analysis has several strengths. First, we performed several subgroup analyses examining the impact of our study methodologies on the treatment effect, such as comparing the pooled effect from studies that required imputation of the mean and SD with studies that did not require imputation. Secondly, we examined the effect of different LPV/r regimens and adjuvant therapies on the treatment outcomes using subgroup analyses. And lastly, we compared the results from studies with a low risk of bias (which were all RCTs, coincidentally) with the results from studies with a high risk of bias (which were all observational and non-randomized studies). Compared with previous meta-analyses, our systematic review included more studies involving a larger sample size of patients, which helped improve the power and precision of our analyses. This was possible, in part, due to additional database searches conducted in Chinese literature sources. Additionally, we evaluated the quality of our evidence using the GRADE framework, which was not done in previous reviews.

However, our study also has several key limitations. Firstly, our subgroup analyses by different regimens and adjuvants often consist of many single-study subgroups, which severely limits the applicability of our subgroup analyses. Furthermore, a majority of our included studies are non-randomized observational studies, which are prone to biases and increased heterogeneity. According to ROBINS-I, all of our included observational studies were rated as having a serious or critical risk of bias, mainly due to potential confounding factors or inadequate descriptions of treatment regimes. Recent reports have shown that there has been a general decline in the quality of research articles and clinical trials [129,130] during the COVID-19 pandemic due to the increased pace of publications, which may explain the poorer quality of the articles that we included. Nevertheless, the pooled results from our observational studies were consistent with the pooled results from high or moderate quality RCT studies according to our subgroup analyses, which increases the confidence in our findings.
Conclusion
This systematic review and meta-analysis indicates, based on low to very low quality of evidence, that the use of LPV/r is not significantly associated with reductions in mortality, length of stay, time for positive-to-negative conversion of SARS-CoV-2 nucleic acid test, incidence of mechanical ventilation, or time to body temperature normalization in hospitalized patients with COVID-19. We also found that the use of LPV/r is significantly associated with an increase in adverse events, based on moderate quality of evidence. Considering the lack of efficacy and the risk of increased gastrointestinal and liver-related toxicities, as well as potential drug–drug interactions with other COVID-19 treatments, the use of LPV/r therapy for treating COVID-19 inpatients is not recommended based on the available evidence.

Summary points
- Lopinavir–ritonavir (LPV/r) combination therapy is an antiretroviral medication that was repurposed for the treatment of COVID-19 due to promising results from in vivo and in silico studies involving human coronaviruses.
- In this systematic review and meta-analysis, results from 20 observational studies and 4 randomized controlled trials (n = 10,718) were included to examine the efficacy and safety of LPV/r for treating hospitalized COVID-19 patients.
- A majority of the included RCTs were rated as having some concerns in regards to risk of bias using RoB2, while all of the included observational studies were rated as having serious or critical risk of bias using ROBINS-I.
- The use of LPV/r was not associated with any significant benefit compared with standard of care or adjuvant therapies alone in reducing mortality, length of stay, time for positive-to-negative conversion of SARS-CoV-2 nucleic acid test, incidence of mechanical ventilation, or time to body temperature normalization.
- The use of LPV/r was significantly associated with increased odds of adverse events (OR: 2.88; 95% CI: 1.04–7.95). The most common adverse events observed in the LPV/r group included gastrointestinal side effects and possible hepatotoxicity.
- All efficacy outcomes were based on low to very low quality of evidence, while the outcome of adverse event incidence was based on moderate quality of evidence, according to the GRADE approach.
- Due to the lack of efficacy and increased odds of adverse events, the clinical use of LPV/r for the treatment of hospitalized patients with COVID-19 is not recommended based on the available evidence.

Supplementary data
To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/fvl-2021-0066

Author contributions
J Deng was responsible for the conception and design of the work, as well as for supervising the data acquisition process (including search strategy development, database search, article screening, full-text retrieval, data extraction and risk of bias analyses), data analysis (including meta-analyses, meta-regressions, subgroup analyses and GRADE ratings) and drafting of the final manuscript. F Zhou was responsible for the conception and design of the work, as well as for supervising and contributing to all parts of the data acquisition process (including search strategy development, database search, article screening, full-text retrieval, data extraction and risk of bias analyses) and revised the final manuscript critically for important intellectual content. W Hou, K Heybati, S Ali, O Chang, Z Silver, T Dhivagaran, H Ba Ramaraju, CY Wong, QK Zuo, E Lapshina and M Mellett contributed to all parts of the data acquisition process (including article screening, data extraction, and risk of bias analyses) and revised the final manuscript critically for important intellectual content. The first and corresponding author had full access to all data in the study and is solely responsible for the decision to submit for publication. All authors had given final approval for the final version of the manuscript to be submitted for publication, and all authors agree to be held accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.
Ethical conduct of research
There are no relevant ethical disclosures as only published, aggregate patient data was used for this study. Aggregate patient data extracted by study authors are available upon reasonable request.

References
Papers of special note have been highlighted as: ● of interest; ●● of considerable interest

1. Esakandari H, Nabi-Afjadi M, Fakkari-Afjadi J, Farahmandian N, Miresmaeili S-M, Bahreini E. A comprehensive review of COVID-19 characteristics. Biolo. Prococ. Online 22, 19 (2020).
2. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: a review. Clin. Immunol. 215, 108427 (2020).
3. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta. Biomed. 91(1), 157–160 (2020).
4. Mahase E. COVID-19: WHO declares pandemic because of ‘alarming levels’ of spread, severity, and inaction. BMJ 368, m1036 (2020).
5. Polack FP, Thomas SJ, Kitchin N et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N. Engl. J. Med. 383(27), 2603–2615 (2020).
6. Ramasamy MN, Minassian AM, Ewer KJ. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet 396(10267), 1979–1993 (2021).
7. Jackson LA, Anderson EJ, Rouphael NG et al. An mRNA vaccine against SARS-CoV-2 – preliminary report. N. Engl. J. Med. 383(20), 1920–1931 (2020).
8. Tanne JH. COVID-19: US cases surge but vaccine distribution is slow. BMJ 372 doi: https://doi.org/10.1136/bmj.n42 (2021) (Epub ahead of print).
9. Mills MC, Salisbury D. The challenges of distributing COVID-19 vaccinations. EClinicalMedicine 31, 100674 (2021).
10. Johns Hopkins University. COVID-19 map. https://coronavirus.jhu.edu/map.html
11. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/
12. Mussini C, Falcone M, Nozza S et al. Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT). Clin. Microbiol. Infect. 27(3), 389–395 (2021).
13. Kim PS, Read SW, Fauci AS. Therapy for early COVID-19: a critical need. Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT). Lancet Infect. Dis. 21(5), E121 (2020).
14. Khuroo MS. Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal. Int. J. Antimicrob. Agents 56(3), 106101 (2020).
15. Beigel JH, Tomashek KM, Dodds LE et al. Remdesivir for the treatment of COVID-19 - final report. N. Engl. J. Med. 383(19), 1813–1826 (2020).
16. RECOVERY Collaborative Group, Horby P, Lim WS et al. Dexamethasone in hospitalized patients with COVID-19. N. Engl. J. Med. 384(8), 693–704 (2021).
17. Tomazini BM, Maia IS, Cavalcanti AB et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA 323(13), 1307–1316 (2020).
18. MAGRO P, Zanella I, Pescarolo M, Castelli F, Quiros-Roldan E. Lopinavir/ritonavir: repurposing an old drug for HIV infection in COVID-19 treatment. Biomed. J. 44(1), 43–53 (2020).
19. Lou Z, Sun Y, Rao Z. Current progress in antiviral strategies. Trends Pharmacol. Sci. 35(2), 86–102 (2014).
20. L´opez Aspiroz E, Santos Buelga D, Cabrera Figueroa S et al. Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patients. Ther. Drug Monit. 33(5), 573–582 (2011).
21. Uzunova K, Filipova E, Pavlova V, Vekov T. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2. Biomed. Pharmacother. 131, 110668 (2020).
A previous systematic review assessing the efficacy and safety of lopinavir–ritonavir for the treatment of COVID-19.

Bhattacharyya A, Kumar S, Sarma P et al. Safety and efficacy of lopinavir/ritonavir combination in COVID-19: a systematic review, meta-analysis, and meta-regression analysis. Indian J. Pharmacol. 52(4), 313–323 (2020).

A previous systematic review assessing the efficacy and safety of lopinavir–ritonavir for the treatment of COVID-19.

Liu XS. Sample size and the precision of the confidence interval in meta-analyses. Ther. Innov. Regul. Sci. 49(4), 593–598 (2015).

Deng J, Zhou F, Hou W et al. The prevalence of depression, anxiety, and sleep disturbances in COVID-19 patients: a meta-analysis. Ann. NY Acad. Sci. 1486(1), 90–111 (2021).

Deng J, Zhou F, Hou W et al. The prevalence of depressive symptoms, anxiety symptoms and sleep disturbance in higher education students during the COVID-19 pandemic: a systematic review and meta-analysis. Psychiatry Res. 301, 113863 (2021).

Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Wiley, NJ, USA (2008).

Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339, b2535 (2009).

Schiavo JH. PROSPERO: an international register of systematic review protocols. Med. Ref. Serv. Q. 38(2), 171–180 (2019).
82. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 315(7109), 629–634 (1997).
83. Fagerland MW. Evidence-based medicine and systematic reviews. In: *Research in Medical and Biological Sciences*. Elsevier, 431–461 (2015).
84. Duval S, Tweedie R. A nonparametric ‘trim and fill’ method of accounting for publication bias in meta-analysis. *J. Am. Stat. Assoc.* 95(449), 89–98 (2000).
85. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. *Biometrics* 56(2), 455–463 (2000).
86. Li Y, Xie Z, Lin W et al. Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial. *Med (N Y)* 1(1), 105–113.e4 (2020).
87. Wen CY, Xie ZW, Li YP et al. The efficacy and safety of lopinavir/ritonavir and arbidol in patients with coronavirus disease 2019. *Chinese Journal of Internal Medicine* 59(8), 605–609 (2020).
88. Gao G, Wang A, Wang S et al. Brief report: retrospective evaluation on the efficacy of lopinavir/ritonavir and chloroquine to treat nonsevere COVID-19 patients. *J. Acquir. Immune Defic. Syndr.* 85(2), 239–243 (2020).
89. Levy C, Lassailly G, Parmentier E, Duhurcq T, Mathurin P, Poissy J. Caution with the use of lopinavir/ritonavir in severely ill patients for the treatment of SARS-CoV-2: a report of severe jaundice. *Am. J. Gastroenterol.* 115(10), 1716–1718 (2020).
90. Grimaldi D, Aissaoui N, Blonz G et al. Characteristics and outcomes of acute respiratory distress syndrome related to COVID-19 in Belgian and French intensive care units according to antiviral strategies: the COVADIS multicentre observational study. *Ann. Intensive Care* 10(1), 131 (2020).
91. Lecronier M, Beurton A, Burel S et al. Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis. *Crit. Care* 24(1), 418 (2020).
92. Vernaz N, Agoritsas T, Calmy A et al. Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs. *Swiss Med. Wkly* 150, w20466 (2020).
93. Echarte-Morales J, Minguito-Carazo C, Del Castillo-García S et al. Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19. *J. Electrocardiol.* 64, 30–35 (2021).
94. Karolylj M, Pawelka E, Mader T et al. Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients: results from a real-life patient cohort. *Wien. Klin. Wochenschr.* 133(7–8), 284–291 (2021).
95. Hraietch S, Bourrenne J, Kutefian K et al. Lack of viral clearance by the combination of hydroxychloroquine and azithromycin or lopinavir and ritonavir in SARS-CoV-2-related acute respiratory distress syndrome. *Ann. Intensive Care* 10(1), 63 (2020).
96. Wang N, Zhan Y, Zhu L et al. Retrospective multicenter cohort study showsearly interferon therapy is associated with favorable clinical responses in COVID-19 patients. *Cell Host Microbe* 28(3), 455–464.e2 (2020).
97. Liu J-Y, Hua M-X, Du C-J et al. The dual role of anti-viral therapy in the treatment of coronavirus disease 2019. *Eur. Rev. Med. Pharmacol. Sci.* 24(22), 11939–11944 (2020).
98. Chen W, Chen CX, Lyu LW et al. Comparison of therapeutic effects between monotherapy and combination therapy of lopinavir/ritonavir and Arbidol in COVID-19. *China Tropical Medicine* 20(10), 972–975 (2020).
99. Xu X, An W, Xia F et al. Retrospective study on the effectiveness and safety of lopinavir/ritonavir in the treatment of coronavirus disease 2019. *China Pharmacat* 23(7), 1366–1369 (2020).
100. Yao J, Sun XF, Dang LY, Ren F, Huang TT. Clinical effect of lopinavir/ritonavir in the treatment of COVID-19. *Clinical Research and Practice* 5(27), 11–13 (2020).
101. Yu AR, Fan X, Zhao Y et al. Clinical efficacy and safety of lopinavir/ritonavir combined with other antiviral in the treatment of coronavirus disease 2019 (COVID-19). *Herald of Medicine* 39(5), 628–632 (2020).
102. Chen J, Ling Y, Xi XH et al. Efficacies of lopinavir/ritonavir and arbidol in the treatment of novel coronavirus pneumonia. *Zhonghua Chuan Ran Bing Za Zhi* 38(2), 86–89 (2020).
103. Wang J, Lu Q, Zhang B et al. Clinical application and curative effect analysis of lopinavir/ritonavir in severe/critical patients with COVID-19. *Military Medical Journal of South China* 34(8), 563–568 (2020).
104. Lin L. Bias caused by sampling error in meta-analysis with small sample sizes. *PLoS One* 13(9), e0204056 (2018).
105. Zhang Z, Xu X, Ni H. Small studies may overestimate the effect sizes in critical care meta-analyses: a meta-epidemiological study. *Crit. Care* 17(1), R2 (2013).
106. Choy K-T, Wong AY-L, Kaewpreedee P et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication *in vitro*. *Antiviral Res.* 178, 104786 (2020).
107. Wu C-Y, Jan J-T, Ma S-H et al. Small molecules targeting severe acute respiratory syndrome human coronavirus. *Proc. Natl Acad. Sci. U. S. A.* 101(27), 10012–10017 (2004).
108. Zhang L, Liu J, Cao R et al. Comparative antiviral efficacy of viral protease inhibitors against the novel SARS-CoV-2 *in Vitro*. *Virology*. 35(6), 776–784 (2020).
Efficacy of lopinavir–ritonavir combination therapy for the treatment of hospitalized COVID-19 patients

Meta-Analysis

- An *in vitro* study which concluded that the serum concentration of lopinavir and ritonavir may not be sufficient for inhibiting the actions of SARS-CoV-2, based on analyses of Cmax and IC50.

109. Rajagopalan P, Reynolds KS, Kim JS. Clinical pharmacology and biopharmaceutics reviews, center for drug evaluation and research. US FDA (2000). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-226_Kaletra_bipharmr_P1.pdf

110. Gulati A, Boudinot FD, Gerk PM. Binding of lopinavir to human alpha1-acid glycoprotein and serum albumin. *Drug Metab. Dispos.* 37(8), 1572–1575 (2009).

111. Cattaneo D, Cattaneo D, Gervasoni C et al. Does lopinavir really inhibit SARS-CoV-2? *Pharmacol. Rev.* 158, 104898 (2020).

- An observational study highlighting the high incidence of drug-drug interactions in COVID-19 patients treated with lopinavir–ritonavir therapy.

112. Mangum EM, Graham KK. Lopinavir–ritonavir: a new protease inhibitor. *Pharmacotherapy* 21(11), 1352–1363 (2001).

113. Sulkowski MS. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. *Clin. Infect. Dis.* 38(Suppl. 2), S90–S97 (2004).

114. Canta F, Marrone R, Bonora S et al. Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients. *J. Antimicrob. Chemother.* 55(2), 280–281 (2005).

115. Macías J, Pinilla A, Lao-Dominguez FA et al. High rate of major drug-drug interactions of lopinavir–ritonavir for COVID-19 treatment. *Sci. Rep.* 10(1), 20958 (2020).

116. Kubin CJ, Hammer SM. Antiretroviral agents. In: *Infectious Diseases.* Elsevier, 1434–1453 (2010).

117. Sevrioukova IF, Poulos TL. Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir. *Proc. Natl Acad. Sci. U. S. A.* 107(43), 18422–18427 (2010).

118. Chandwani A, Shuter J. Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. *Ther. Clin. Risk Manag.* 4(5), 1023–1033 (2008).

119. Lopinavir and ritonavir. In: *Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions.* Elsevier, 2159–2162 (2006).

120. National Institutes of Health. Coronavirus disease 2019 (COVID-19) treatment guidelines. NIH, MD, USA (2020). http://www.covid19treatmentguidelines.nih.gov/

121. Infectious Diseases Society of America. Guidelines on the treatment and management of patients with COVID-19 (2021). IDSA, VA, USA, http://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/

122. Tomlinson ES, Lewis DF, Maggs JL, Kroemer HK, Park BK, Back DJ. *In vitro* metabolism of dexamethasone (DEX) in human liver and kidney: the involvement of CYP3A4 and CYP17 (17,20 LYASE) and molecular modelling studies. *Biochem. Pharmacol.* 54(5), 605–611 (1997).

123. Canalejo E, Pacheco MS. Cushing syndrome due to ritonavir-fluticasone interaction. *CMAJ* 184(15), 1714 (2012).

124. Lopinavir and ritonavir tablets, oral use, documentation, president's emergency plan for AIDS relief (PEPFAR) database. US FDA (2018). http://www.accessdata.fda.gov/drugsatfda_docs/pepfar/090371PI.pdf

125. Piliero PJ. Interaction between ritonavir and statins. *Am J. Med.* 112(6), 510–511 (2002).

126. Pastori D, Mezzaroma I, Pignatelli P, Violi F, Lip GYH. Atrial fibrillation and human immunodeficiency virus type-1 infection: a systematic review. Implications for anticoagulant and antiarrhythmic therapy. *Br. J. Clin. Pharmacol.* 85(3), 508–515 (2019).

127. National Institutes of Health. COVID-19 treatment guidelines – antiviral therapy. NIH, MD, USA (2021). http://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/

128. Bhimraj A, Morgan RL, Shumaker AH et al. IDSA guidelines on the treatment and management of patients with COVID-19. *Recommendation 4: Lopinavir/Ritonavir.* IDSA, VA, USA (2020). https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/

129. Bonini S, Maltese G. COVID-19 clinical trials: quality matters more than quantity. *Allergy* 75(10), 2542–2547 (2020).

130. Bramstedt KA. The carnage of substandard research during the COVID-19 pandemic: a call for quality. *J. Med. Ethics* 46(12), 803–807 (2020).